4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Universal Flu Vaccine (UNIVACFLU)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.The aim is to ...
Voir le projet
8
Participants partenaires
TERMINÉ
Universal Influenza Vaccines Secured (UNISEC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of sc ...
Voir le projet
15
Participants partenaires
TERMINÉ
Nasal Pandemic Influenza Vaccine (NASPANVAC)
Date du début: 1 mai 2008, Date de fin: 30 avr. 2012,
"The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan ...
Voir le projet
8
Participants partenaires
TERMINÉ
Dose sparing and increased immunogenicity of a pandemic influenza vaccine by CoVaccine HT (FLUVAC)
Date du début: 1 oct. 2007, Date de fin: 30 sept. 2011,
The risk of a new influenza pandemic is emphasized by a WHO report documenting several hundreds of recent cases of human infection with a new virus strain and approximately 50% mortality. Control or prevention of a pandemic by emergency vaccination depends on availability of products with high efficacy and broad protection. The combination of an effective adjuvant and cell culture technology for a ...
Voir le projet